A first patient in Nanjing just received a lupus treatment that aims at two drivers of the disease at once

For people living with lupus, the immune system turns on the body itself, and treatments often chase one pathway at a time. In Nanjing, doctors at Renji Hospital have now given the first lupus patient a new kind of medicine, LBL-047, designed to engage two disease-driving pathways at once — one in the innate immune system, the first responders, and one in the adaptive system that learns and remembers. The patient is part of the second half of an early trial; the first half, in healthy volunteers, produced the safety data that let doctors proceed. It is a first step, not a proven treatment — but it is the first time this two-target design has been tested in the people it was built to help.

SDG 3 · Good health and well-being — Mechanism: tech innovation